JP2010524909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524909A5 JP2010524909A5 JP2010503582A JP2010503582A JP2010524909A5 JP 2010524909 A5 JP2010524909 A5 JP 2010524909A5 JP 2010503582 A JP2010503582 A JP 2010503582A JP 2010503582 A JP2010503582 A JP 2010503582A JP 2010524909 A5 JP2010524909 A5 JP 2010524909A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- chloro
- gefitinib
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 58
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 15
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 15
- 229960002584 gefitinib Drugs 0.000 claims description 15
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 125000001246 bromo group Chemical group Br* 0.000 claims description 12
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 claims description 12
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 11
- 230000003647 oxidation Effects 0.000 claims description 11
- 238000007254 oxidation reaction Methods 0.000 claims description 11
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- 150000004965 peroxy acids Chemical class 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 238000005984 hydrogenation reaction Methods 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 125000002346 iodo group Chemical group I* 0.000 claims description 5
- MIOWUSCQMNUHTF-UHFFFAOYSA-N (7-methoxyquinazolin-6-yl) acetate Chemical compound C1=NC=C2C=C(OC(C)=O)C(OC)=CC2=N1 MIOWUSCQMNUHTF-UHFFFAOYSA-N 0.000 claims description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 4
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- -1 acetoxy compound XIII Chemical compound 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000000852 hydrogen donor Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 238000006396 nitration reaction Methods 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 claims description 2
- VWBHHSJRPOSFGG-UHFFFAOYSA-N (4-chloro-7-methoxyquinazolin-6-yl) acetate Chemical compound C1=NC(Cl)=C2C=C(OC(C)=O)C(OC)=CC2=N1 VWBHHSJRPOSFGG-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- NMILGIZTAZXMTM-UHFFFAOYSA-N 4-propylmorpholine Chemical class CCCN1CCOCC1 NMILGIZTAZXMTM-UHFFFAOYSA-N 0.000 claims description 2
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims description 2
- JLVTVCRXFMLUIF-UHFFFAOYSA-N O-Desmorpholinopropyl Gefitinib Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 JLVTVCRXFMLUIF-UHFFFAOYSA-N 0.000 claims description 2
- ANGPUOTYQQFHKN-UHFFFAOYSA-N [4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl] acetate Chemical compound C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 ANGPUOTYQQFHKN-UHFFFAOYSA-N 0.000 claims description 2
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 claims description 2
- 230000000397 acetylating effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 150000004675 formic acid derivatives Chemical class 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 2
- 0 *CCC*c(cc1C=O)c(*)cc1[N+]([O-])=O Chemical compound *CCC*c(cc1C=O)c(*)cc1[N+]([O-])=O 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GQYBQYWUTWWHOP-QVDQXJPCSA-N CCC(CC(C(C1=O)=C2)N=C[C@H]1N=C)=C2O Chemical compound CCC(CC(C(C1=O)=C2)N=C[C@H]1N=C)=C2O GQYBQYWUTWWHOP-QVDQXJPCSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN745MU2007 | 2007-04-16 | ||
| PCT/GB2008/001343 WO2008125867A2 (en) | 2007-04-16 | 2008-04-16 | Process for the preparation of gefitinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010524909A JP2010524909A (ja) | 2010-07-22 |
| JP2010524909A5 true JP2010524909A5 (enExample) | 2011-06-02 |
Family
ID=39537889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503582A Pending JP2010524909A (ja) | 2007-04-16 | 2008-04-16 | ゲフィチニブの製造方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8350029B2 (enExample) |
| EP (1) | EP2155656A2 (enExample) |
| JP (1) | JP2010524909A (enExample) |
| KR (1) | KR20100017101A (enExample) |
| AU (1) | AU2008237749B2 (enExample) |
| CA (1) | CA2683694A1 (enExample) |
| NZ (1) | NZ580382A (enExample) |
| WO (1) | WO2008125867A2 (enExample) |
| ZA (1) | ZA200907191B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008125867A2 (en) | 2007-04-16 | 2008-10-23 | Cipla Limited | Process for the preparation of gefitinib |
| CN102557977B (zh) * | 2010-12-20 | 2014-07-30 | 浙江海正药业股份有限公司 | 埃罗替尼的合成中间体及其制备方法 |
| CN102911125B (zh) * | 2011-08-05 | 2016-03-02 | 浙江九洲药业股份有限公司 | 一种吉非替尼中间体的制备方法 |
| KR101457453B1 (ko) * | 2012-05-31 | 2014-11-04 | 주식회사 종근당 | 게피티닙의 제조방법 및 이의 제조에 사용되는 중간체 |
| WO2014147631A1 (en) | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
| CN103304491A (zh) * | 2013-06-17 | 2013-09-18 | 连云港盛和生物科技有限公司 | 一种吉非替尼的制备方法 |
| CN103864702B (zh) * | 2014-02-27 | 2016-05-11 | 福建医科大学 | 一种在水相中微波催化制备喹唑酮化合物的方法 |
| CN104016929B (zh) * | 2014-06-25 | 2016-03-30 | 北京理工大学 | 一种合成喹唑啉-4(3h)-酮的方法 |
| CN105503748A (zh) * | 2015-12-31 | 2016-04-20 | 哈药集团技术中心 | 一种吉非替尼的制备方法 |
| CN107915643A (zh) * | 2016-10-09 | 2018-04-17 | 浙江瑞博制药有限公司 | 一种5‑(3‑羟基丙氧基)‑4‑甲氧基‑2‑硝基甲酯苯甲酸的制备方法 |
| CN110776471A (zh) * | 2019-11-28 | 2020-02-11 | 王爱平 | 一种抑制肿瘤细胞药物的合成方法 |
| CN114957200B (zh) * | 2022-05-31 | 2024-07-26 | 湖南华腾制药有限公司 | 抗癌药物埃克替尼关键中间体的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| AU719327B2 (en) * | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| IT1296985B1 (it) | 1997-12-19 | 1999-08-03 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| KR20020032612A (ko) * | 1999-09-21 | 2002-05-03 | 다비드 에 질레스 | 퀴나졸린 유도체 및 그의 의약으로서의 용도 |
| US8367824B2 (en) * | 2002-01-28 | 2013-02-05 | Ube Industries Ltd. | Process for producing quinazolin-4-one derivative |
| GB0221245D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Chemical process |
| GB0320793D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
| WO2005070909A1 (en) * | 2004-01-22 | 2005-08-04 | Natco Pharma Limited | An improved process for the preparation of gefitinib |
| WO2008125867A2 (en) | 2007-04-16 | 2008-10-23 | Cipla Limited | Process for the preparation of gefitinib |
-
2008
- 2008-04-16 WO PCT/GB2008/001343 patent/WO2008125867A2/en not_active Ceased
- 2008-04-16 AU AU2008237749A patent/AU2008237749B2/en not_active Expired - Fee Related
- 2008-04-16 CA CA002683694A patent/CA2683694A1/en not_active Abandoned
- 2008-04-16 US US12/595,812 patent/US8350029B2/en not_active Expired - Fee Related
- 2008-04-16 JP JP2010503582A patent/JP2010524909A/ja active Pending
- 2008-04-16 KR KR1020097023677A patent/KR20100017101A/ko not_active Withdrawn
- 2008-04-16 EP EP08737004A patent/EP2155656A2/en not_active Withdrawn
- 2008-04-16 NZ NZ580382A patent/NZ580382A/en not_active IP Right Cessation
-
2009
- 2009-10-15 ZA ZA200907191A patent/ZA200907191B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524909A5 (enExample) | ||
| KR101472686B1 (ko) | 벤즈이미다졸 유도체의 제조방법 | |
| JP2009527517A5 (enExample) | ||
| JP4977353B2 (ja) | シクロブタンテトラカルボキシレート化合物及びその製造方法 | |
| CN112898192A (zh) | 一种n-酰基吲哚化合物的制备方法 | |
| JP2019531265A (ja) | アルコールの直鎖及び分枝官能化アルカンへの変換 | |
| Yang et al. | Visible-light-driven four-component diacylation of styrenes with acyl azolium salts: carbonylative synthesis of 1, 4-diketones | |
| JP2009062360A (ja) | シナカルセットの製造方法 | |
| CN116786165B (zh) | 一种低价钨催化苯胺的可控氧化脱氢偶联的方法 | |
| JP2013522273A5 (enExample) | ||
| CN111303040A (zh) | 一种一锅法制备咪唑-1-乙酸的方法 | |
| CN107162920B (zh) | 一种r-1-氨基-2-丙醇的制备方法 | |
| JP2017502009A (ja) | シロドシン及びその中間体の製造方法 | |
| US6476279B2 (en) | Method of making fluorinated alcohols | |
| CN115710213A (zh) | 一种顺式手性3-氟-4-羟基哌啶及其衍生物的制备方法 | |
| JP5129699B2 (ja) | メチル=ヘキサデカ−8−イノアートの製造方法 | |
| JP4288311B2 (ja) | 光学活性アミノアルコールの製造方法 | |
| JP2010037206A (ja) | 光学活性なo−メチルセリンまたはその塩の製造法 | |
| CN116986969B (zh) | 一种氟代烯丙醇的合成方法 | |
| WO2004024672A1 (ja) | アミン誘導体 | |
| CN113387874B (zh) | 6,6-二烷基哌啶-2-羧酸化合物的合成方法 | |
| WO2020183295A1 (en) | Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof | |
| CN117088826B (zh) | 一种可见光促进的多取代噁唑的合成方法 | |
| JP5969581B2 (ja) | エステル化合物の製造方法およびこれにより製造されたエステル化合物 | |
| WO2003014067A1 (fr) | Methode de production d'un compose beta-oxonitrile ou d'un sel de metal alcalin dudit compose |